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Abstract
Background: Prostaglandin E2 (PGE2) is the major product of Cyclooxygenase-2 (COX-2) in colorectal cancer
(CRC). We aimed to assess PGE2 cell surface receptors (EP 1–4) to examine the mechanisms by which PGE2
regulates tumour progression.
Methods: Gene expression studies were performed by quantitative RT-PCR. Cell cycle was analysed by flow
cytometry with cell proliferation quantified by BrdU incorporation measured by enzyme immunoassay.
Immunohistochemistry was employed for expression studies on formalin fixed paraffin embedded tumour tissue.
Results: EP4 was the most abundant subtype of PGE2 receptor in HT-29 and HCA7 cells (which show COX-2
dependent PGE2 generation) and was consistently the most abundant transcript in human colorectal tumours (n
= 8) by qRT-PCR (ANOVA, p = 0.01). G0/G1 cell cycle arrest was observed in HT-29 cells treated with SC-236
5 mM (selective COX-2 inhibitor) for 24 hours (p = 0.02), an effect abrogated by co-incubation with PGE2 (1 mM).
G0/G1 arrest was also seen with a specific EP4 receptor antagonist (EP4A, L-161982) (p = 0.01). Treatment of
HT-29 cells with either SC-236 or EP4A caused reduction in intracellular cAMP (ANOVA, p = 0.01). Early
induction in p21WAF1/CIP1 expression (by qRT-PCR) was seen with EP4A treatment (mean fold increase 4.4, p =
0.04) while other genes remained unchanged. Similar induction in p21WAF1/CIP1 was also seen with PD153025 (1
mM), an EGFR tyrosine kinase inhibitor, suggesting EGFR transactivation by EP4 as a potential mechanism. Additive
inhibition of HCA7 proliferation was observed with the combination of SC-236 and neutralising antibody to
amphiregulin (AR), a soluble EGFR ligand. Concordance in COX-2 and AR localisation in human colorectal
tumours was noted.
Conclusion: COX-2 regulates cell cycle transition via EP4 receptor and altered p21WAF1/CIP1 expression. EGFR
pathways appear important. Specific targeting of the EP4 receptor or downstream targets may offer a safer
alternative to COX-2 inhibition in the chemoprevention of CRC.
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Background
Colorectal cancer (CRC) remains a leading cause of cancer
death, with worldwide 1 million new cases each year and
as many as half a million cancer deaths annually [1].
Cyclooxygenase-2 (COX-2) expression is increased in the
majority of colorectal tumours [2] and this induction is
associated with advanced tumour stage and correlates
with poor clinical outcomes [3]. Non-steroidal anti-
inflammatory drugs (NSAIDs), which inhibit COX activ-
ity, show anti-neoplastic effects in-vitro [4,5] and human
studies have demonstrated their use to be associated with
a reduced incidence of colorectal neoplasia [6,7]. While
more recent studies have confirmed the chemo-preventive
activity of COX-2 selective NSAIDs [8-10], it is also clear
that long term therapy with COX-2 inhibitors is associ-
ated with an unacceptable increase in the risk of cardio-
vascular events [9,11].
The anti-neoplastic properties of NSAIDs result from the
inhibition of prostaglandin generation, particularly pros-
taglandin E2 (PGE2), the most abundant in-vivo product of
COX-2 activity in colorectal cancer cells [12,13]. The bio-
logical activity of PGE2 is mediated by binding to cell sur-
face receptors. There are four subtypes of EP receptor
(EP1, EP2, EP3, and EP4) with the majority localised to
the plasma membrane. The binding of prostaglandins to
cell surface receptors triggers changes in second messen-
gers [14].
PGE2 modulates processes fundamental to tumour cell
survival such as enhanced proliferation and resistance to
apoptosis [4,15-17], however, the precise molecular
mechanisms remain unclear. There is therefore a strong
rationale to seek a more profound understanding of the
downstream targets of COX-2 activity. Selective COX-2
inhibitors have shown promise as chemo-preventive
agents [18], but their adverse cardiovascular effects have
undermined their suitability for long term use [9,11].
Renewed attention must now therefore focus on the
altered signalling occurring downstream of COX-2 in can-
cer as a source for new refined therapeutic targets.
Methods
Cell culture
HT-29 cells were purchased from the ATCC (Rockville,
MD) and maintained in McCoy's 5 A medium containing
1.5 mM L-glutamine, 10% FBS, penicillin 100 U/ml and
streptomycin 100 mg/ml. HCA7 cells were kindly donated
by Susan Kirkland (ICRF, London, UK) and were cultured
in DMEM with 10% FBS, supplemented with 1 mM
sodium pyruvate and 100 mg/ml kanamycin. SC236, a
selective COX-2 inhibitor was a gift from Dr. Peter Isakson
(Searle, Skokie, IL). PGE2 was purchased from Cayman
(St. Louis, MO). L-161982 (EP4A), a selective antagonist
of the EP4 receptor was a kind gift of Merck Frosst, Canada
[19]. PD153035 (EGFR tyrosine kinase inhibitor) was
purchased from Calbiochem (La Jolla, CA). Wortmannin
was purchased from Sigma Aldrich (Dublin, Ireland).
Quantitative RT-PCR
Total RNA was isolated from cells and tissue following
homogenisation in RNA lysis buffer (Qiagen Ltd. GmbH,
Germany) supplemented with 1% b-mercaptoethanol.
Extraction was performed using RNeasy™ Mini Kits (Qia-
gen Ltd. GmbH, Germany). Total RNA (1 mg) was reverse
transcribed using Moloney Murine Leukaemia Virus
(MMLV) reverse transcriptase (Promega, Madison, WI)
according to the manufacturer's instructions. Gene expres-
sion was quantified by RT-PCR using SYBR Green Univer-
sal Master Mix (Roche Diagnostics Corp., Indianapolis,
IN). Reactions were carried out in a 96 well format in the
ABI 7700 Sequence Detector (Perkin Elmer/Applied Bio-
systems, UK). Results were then normalized to 18S rRNA
amplified from the same cDNA mix. Sequences of the
primer pairs used are listed below.
EP1- F ATG GTG GGC CAG CTT GTC
EP1- R GCC ACC AAC ACC AGC ATT G
EP2- F TGC CTT TCA CGA TTT TTG CA
EP2- R TTA ATT GAT AAA AAC CTA AGA GCT TGG A
EP3- F TCT CCG CTC CTG ATA ATG ATG TT
EP3- R TCT GCT TCT CCG TGT GTG TCT T
EP4-F CGA CCT TCT ACA CGC TGG TAT G
EP4-R CCG GGC TCA CCA ACA AAG T
Amphireg-F CTC GGG AGC CGA CTA TGA CTA
Amphireg-R GCT TAA CTA CCT GTT CAA CTC TGA CTG A
CyclinD1-F CTG GAG GTC TGC GAG GAA CA
CyclinD1-R TGC AGG CGG CTC TTT TTC
CDK4-F TGT TGT CCG GCT GAT GGA
CDK4-R AAA CAC AGG GTT ACC TTG ATC TC
CDK6-F CAA CTA GGA AAA ATC TTG GAC GTG AT
CDK6-R TTG GTT GGG CAG ATT TTG AAT
p21-F GCA GAC CAG CAT GAC AGA TTT CTA
p21-R GCG GAT TAG GGC TTC CTC TTBMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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p27-F CCT GCA ACC GAC GAT TCT TC
p27-R TCT TAA TTC GAG CTG TTT ACG TTT GA
Immunohistochemical staining for COX-2 and 
amphiregulin
Samples of formalin fixed, paraffin embedded tissue were
deparaffinised and rehydrated in Xylene and Methanol.
Detection of COX-2. Endogenous peroxidase activity was
quenched with 0.3% H2O2 in Methanol. Specimens were
blocked in 1.5% normal serum and then incubated with
antibody to COX-2 (Rabbit polyclonal anti-human COX-
2, Cayman Chemical Co.) diluted 1/200, followed by sec-
ondary antibody and ABC complex from Vectastain Elite
kit (Vector Laboratories, Burlingame, CA). Sections were
exposed to diaminobenzidine (DAB) (Sigma Aldrich,
Dublin, Ireland) and counterstained with hematoxylin
(Sigma Aldrich, Ireland) and mounted using DPX (BDH,
Poole, UK). Detection of Amphiregulin. Antigen retrieval
was performed by heating slides in 10 mM citrate buffer
(pH6.0) for 4 minutes in a pressure cooker. Blocking was
performed with goat serum for 30 minutes. Slides were
then incubated with primary antibody to amphiregulin
(rabbit polyclonal to Amphiregulin by Abcam, Cam-
bridge, MA) diluted 1/200 in ChemMate™ antibody dilu-
ent (DakoCytomation, Galway, Ireland) for 1 hour and
staining completed using the ChemMate™ DAKO Envi-
sion™ detection kit (DakoCytomation, Galway, Ireland)
visualisation, counterstaining and mounting were per-
formed as outlined above.
Prostaglandin analysis and cAMP detection by enzyme 
immunoassay
Competitive enzyme immunoassay (EIA) was used to
determine PGE2 levels in culture media in 96-well format
by Assay Designs (Ann Arbor, MI, USA). Prostaglandin
concentration was calculated using the optical density of
the samples in relation to a standard curve generated by
dilutions of a standard provided. Quantitative determina-
tion of cAMP concentration in cell lysates was performed
using the cAMP (low pH) immunoassay by R and D Sys-
tems (Abingdon, Oxon, UK). Adherent cells were lysed in
0.1 N HCl for 10 min at 37°C and supernatants were
assayed according to manufacturer's instructions in a 96
well plate. cAMP concentrations were calculated using a
similar standard curve method.
Cell proliferation (BrdU incorporation)
Cell proliferation assays were carried out using the BrdU
(colorimetric) cell proliferation ELISA (Roche Applied
Science, Dublin, Ireland) according to manufacturer's
instructions. Cells were seeded at 5 × 103/well in 96 well
plates and following overnight serum starvation were
treated with vehicle or drug. Amphiregulin neutralisation
was with anti-human neutralising AR antibody (AR-ab)
from Stratech Scientific (Soham, Cambridgeshire, UK).
Cell cycle analysis
HT-29 cells were seeded at a density of 1 × 106/well in 6
well plates and treated with drug or vehicle for 24 hours.
Adherent cells were suspended using trypsin-EDTA for 3–
5 min at 37°C and were fixed overnight in 75% ethanol at
4°C then washed and resuspended in a solution of PBS
containing 0.1% Triton X-100, 0.05 mg/ml of DNase-free
RNase and a 50 mg/ml propidium iodide (Molecular
Probes, Leiden, NL) in the dark for 30 min. Cells were
resuspended in PBS prior to analysis in a FACScalibur
flow cytometer (Becton Dickinson, Oxford, UK) with
measurement of fluorescence emission at >575 nm (FL3).
Analysis of cell cycle distribution (DNA index) was per-
formed using CellQuest™ (Becton Dickinson, Oxford,
UK).
Tumour collection
The protocol was approved by the Ethics (Medical
Research) Committee of Beaumont Hospital, Dublin and
all patients provided written, informed consent. Samples
of colorectal tumour/normal were obtained from patients
at the time of surgery and were immediately placed in
RNAlater solution (Qiagen GmbH, Germany) or fixed in
10% formalin.
Statistical analysis
A one-way analysis of variance (ANOVA) was used to
examine overall differences between multiple groups,
with Bonferroni multiple comparisons test. Two tailed
paired students T-test was used to compare the means of
paired samples. The statistical packages GraphPad InStat
and GraphPad Prism were used. Statistical significance
was set at a P value of less than 0.05, whereas a P value less
than 0.005 was considered highly significant.
Results
EP receptor expression in HT-29 cells is similar to in-vivo 
expression in CRC
EP receptor expression was assessed by qRT-PCR in the
human colon cancer cell line HT-29 (n = 3) and EP4
receptor was the most abundant receptor subtype. A rep-
resentative amplification plot is shown in Figure 1a with
linear amplification of EP4 seen in identical template after
the shortest number of cycles. The transcript for the EP2
receptor was less abundant than EP4 with significantly
less transcript again for both the EP3 and EP1 receptors. A
similar expression pattern of EP receptors was observed in
HCA7 cells, which also generate PGE2 in a COX-2 depend-
ent manner.
EP receptor expression was next assayed in human
tumour samples (n = 8) with a similar expression pattern
in all tumours studied. The EP4 receptor was consistently
the most abundant receptor transcript (shortest number
of cycles to exponential amplification in identical tem-
plate, ANOVA p = 0.0002, Figure 1b). While the numberBMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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EP4 Receptor Expression in HT-29 Cells and in Human CRC Figure 1
EP4 Receptor Expression in HT-29 Cells and in Human CRC. (1a). Representative amplification plot for the various EP 
receptors in HT-29 cells. The no template control (NTC) is indicated by the grey line. (1b) The number of cycles required to 
achieve exponential amplification of identical template from a panel of 8 colorectal tumours by qRT-PCR. The chart shows 
mean values +/- SEM for n = 8. Repeated measures ANOVA (overall) p = 0.0002, significant p values are shown and represent 
Bonferroni multiple comparisons test between selected groups.BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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of cycles to amplification was significantly less for the EP4
receptor than EP1 (p = 0.001) or EP2/EP3 (p = 0.01), no
significant differences were noted in the abundance of the
other EP receptors relative to each other. The relative
abundance of the EP4 receptor in both cancer cell lines
and in human tumour tissue suggested that signalling
through this receptor might therefore be important in
how PGE2 regulates tumour cell phenotypes.
PGE2 generation in HT-29 is associated with cAMP 
generation via EP4 receptor
While others have suggested that HT-29 cells lack the abil-
ity to generate prostaglandins through COX-2 activity
[20], we confirmed that PGE2 is generated in a COX-2
dependent fashion in HT-29 cells and with EP4 receptor
activation. Significant PGE2 generation by HT-29 cells was
observed in control cells and this was reduced in a dose
dependent manner by SC236, a COX-2 selective inhibitor
(Figure 2a). The EP4 receptor signals by mediating
changes in cAMP production via adenylate cyclase. The
activity of this receptor (and thus indirectly EP4 protein
expression) was demonstrated by measuring the genera-
tion of cAMP by cells with receptor modulation. Figure 2b
shows the reduction in intracellular cAMP levels follow-
ing both inhibition of PGE2 production by SC-236 and by
a specific antagonist of the EP4 receptor (L-161982) con-
firming functional EP4 activity.
PGE2 dependent regulation of cell cycle occurs through 
EP4 receptor
SC-236 increased the number of cells in the G0/G1 phase
of the cell cycle over a range of doses. This G0/G1 arrest
was much more marked with higher doses of the inhibitor
(see Figure 3a). Interestingly, the effects of the inhibitor
were not 'rescued' by co-incubation with exogenous pros-
taglandin at the higher dose. However, at doses of SC-236
in the low micromolar range (sufficient to abolish >90%
of PGE2  production), a G0/G1  cell cycle arrest was
observed which was reversed by co-incubation with exog-
enous PGE2 (Figure 3b). Cell cycle arrest was also seen on
incubation with L-161982 suggesting that activation of
the EP4 receptor by endogenous PGE2 plays a role in the
regulation of cell cycle progression in HT-29 cells.
Enhanced expression of p21WAF1/CIP1 mediated by EP4 
receptor
The ability of selective EP4 receptor inhibition to modu-
late changes in the expression of cell cycle regulation
genes was assessed to evaluate potential mechanisms for
the observed phenotype. The expression of Cyclin D1, the
cyclin dependent kinases CDK4 and CDK6 and finally the
CDK inhibitors p21WAF1/CIP1 and p27KIP1 were evaluated.
The results are summarised in Figure 4a. A significant
induction in p21WAF1/CIP1  expression was seen after 4
hours with EP4 receptor antagonism (mean change 4.4
fold, p = 0.04). Expression of the other cell cycle regula-
tion genes remained unchanged. Similar induction in
p21WAF1/CIP1 expression was observed with PD153035, an
EGFR tyrosine kinase inhibitor (p = 0.001), an effect not
seen with the PI-3 kinase inhibitor wortmannin, suggest-
ing transactivation of EGFR by EP4 as the likely mecha-
nism for the induction of p21WAF1/CIP1.
Relationship between EGFR and PGE2 in regulating of cell 
proliferation
EGFR transactivation appears important in PGE2 signal-
ling and our results suggested a role in regulation of cell
cycle progression genes and thus proliferation. PGE2
mediates EGFR activation by the release of EGFR ligands.
Amphiregulin (AR) is known to be the most abundant
COX-2 dependent generation of PGE2 and signalling through  the EP4 receptor Figure 2
COX-2 dependent generation of PGE2 and signalling 
through the EP4 receptor. (2a) Generation of PGE2 in 
HT-29 cells over 15 minutes following treatment with vari-
ous doses of the COX-2 inhibitor SC-236 or Aspirin (ASA, 
200 mM) for 4 hours. Values are the mean +/- standard error 
of the mean (n = 3). One way ANOVA p = 0.0001; * p = 0.01 
** p = 0.001 (Bonferroni multiple comparisons test between 
selected groups). (2b) Intracellular cAMP concentrations fol-
lowing treatment with SC236 (5 mM) or L-161–982 (10 mM) 
for 30 mins. The chart shows mean values +/- SEM for n = 3. 
One way ANOVA (overall) p = 0.01, p values shown are for 
Bonferroni multiple comparisons test between selected 
groups.BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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Regulation of Cell Cycle Progression in HT-29 Cells Figure 3
Regulation of Cell Cycle Progression in HT-29 Cells. (3a) Representative images of cell cycle distribution assessed by 
flow cytometry under the conditions outlined. (3b) Percentage of cells in the G1 peak in repeated flow experiments is shown 
(SC236 (5 mM) +/- PGE2 1 mM or L-161–982 (10 mM) The chart shows mean values +/- SEM for n = 5. One way ANOVA (over-
all) p = 0.01, p values shown are for Bonferroni multiple comparisons test between selected groups.BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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Expression of p21WAF1/CIP1 in HT-29 Cells is regulated by EGFR trans-activation through the EP4 receptor Figure 4
Expression of p21WAF1/CIP1 in HT-29 Cells is regulated by EGFR trans-activation through the EP4 receptor. (4a) 
Expression of p21 by qRT-PCR in HT-29 cells following treatment with EP4A (L-161,982) 10 mM for 4 hours. Values shown are 
the Mean +/- SEM for n = 3. p values are for paired students t-test. (4b) Expression of p21 by qRT-PCR in HT-29 cells showing 
a comparison of the effects of EP4A (10 mM), a EGFR tyrosine kinase inhibitor (PD153025, 1 mM) and the PI3 Kinase inhibitor 
(Wortmannin, 1 mM). Values shown are the Mean +/- SEM (n = 3). One way ANOVA (overall) p = 0.0001, p values shown are 
for Bonferroni multiple comparisons test between selected groups.BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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EGFR ligand in HCA7 cells [21], which exhibit PGE2
dependent proliferation and therefore constitute an excel-
lent in-vitro model to examining interplay between pros-
taglandins and EGFR.
The effect on HCA7 cell proliferation of a neutralising
antibody to AR (ARab) both alone and in combination
with SC-236 was evaluated. Effects of SC-236 on cell pro-
liferation were again evident (33% mean reduction in
proliferation, p = 0.001). At low concentration (0.1 – 1.0
mg/ml) the AR neutralizing antibody (ARab) had no
effect (not shown), however at higher concentrations (10
mg/ml) a small effect (20% mean reduction, p = 0.05) on
cell proliferation was noted (Figure 5). The effect of com-
bined treatment with COX-2 inhibitor and ARab was
greater than that of either ARab (p = 0.001) or SC-236 (p
= 0.05) alone, resulting in a greater than 50% reduction in
proliferation relative to control.
Relationship between expression of COX-2 and 
amphiregulin in CRC
The relationship between COX-2 and AR expression in
human CRC was next examined. The expression of
amphiregulin (AR) transcript was quantified in 10
tumour/normal pairs by qRT-PCR and correlated with
expression of COX-2 in the same samples. AR expression
was greater in tumour relative to normal in 7 of 10
patients (Mean fold difference = 4.2, p = 0.07 for paired t-
test). A non-significant positive correlation was observed
(Pearson r = 0.50, p = 0.13) between the tumour/normal
differences for COX-2 and AR in the samples assayed.
Closer inspection revealed higher than anticipated levels
of AR expression in the normal colon (explaining the fail-
ure to observe a significant correlation). In an effort to
better understand the relationship, immunohistochemis-
try on paired tumour and normal mucosa from an addi-
tional 20 patients was performed to evaluate expression of
AR and COX-2. COX-2 immunoreactivity was virtually
absent in normal colonic mucosa. AR expression was
detectable in all of the normal samples, with a character-
istic pattern of expression, being observed in the cyto-
plasm of the surface columnar epithelial cells while
absent or reduced in crypt epithelial cells (Figure 6a). Dif-
ferential expression of AR along the colonic crypt has been
described previously [22]. COX-2 and AR expression in
tumour tissue showed greater variability. Six of twenty
cases (30%) showed absent or low level (<5% of cells pos-
itive) for both COX-2 and AR. In the remainder of
patients, significant immunoreactivity for both molecules
was observed and a concordance was observed in the
localisation of positive staining within tumour specimens
(representative images are presented in Figure 6b). COX-
2 expression was observed exclusively in the cytoplasm of
tumour epithelial cells. AR expression was mostly cyto-
plasmic, but focal areas of positive nuclear staining were
also observed (Figure 6c).
Discussion
COX-2 expression in colorectal tumours is biologically
and clinically important [3,16] and PGE2 is the major
product of COX-2 activity in cancer cells [12,13]. Four
subtypes of membrane PGE2 receptor have been character-
ised (EP1–4), although the relative contribution of each
of these to key signalling events in cancer has not been
fully elucidated. We show that all of the EP receptor sub-
types are expressed in human colorectal cancers and that
EP4 receptor is predominant. We also demonstrate that
the HT-29 cells share this relative distribution of recep-
tors, validating its use as an in-vitro model.
Animal studies demonstrate that all four EP receptors are
expressed in azoxymethane (AOM) induced tumours in
rats [23]. Forced expression of COX-2 in murine mam-
mary epithelial cells (with generation of PGE2 as the prin-
cipal product) is associated with induction of EP 1, 2 and
4 receptors and down regulation of EP3 [24]. Knockout
mice deficient in all four subtypes of EP receptor and with
deletions of the DP, FP, IP or TP receptors have been gen-
erated. The formation of aberrant crypt foci (ACF) follow-
ing AOM treatment was only different in animals with
deletions of the EP1 [25] and the EP4 receptor [26]. While
no difference in ACF formation with deletion of the EP2
receptor was detected; decreased polyp formation has
been observed with deletion of the EP2 receptor in
ApcD716 mice [27].
Amphiregulin and COX-2 dependent cell growth in colon  cancer cells Figure 5
Amphiregulin and COX-2 dependent cell growth in 
colon cancer cells. Bar chart shows the effect on cell pro-
liferation (as assessed by BrdU Incorportion) of a neutralising 
antibody to amphiregulin (ARab, 10 mg/ml), a COX-2 inhibi-
tor (SC-236, 5 mM) or a combination of both for 24 hours. 
Values shown are the Mean +/- SEM for n = 5. One way 
ANOVA (overall) p = 0.0001, p values shown are for Bonfer-
roni multiple comparisons test between selected groups.BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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Amphiregulin expression in normal colonic mucosa Figure 6
Amphiregulin expression in normal colonic mucosa. 6a. Positive staining (brown) for amphiregulin is seen in this sec-
tion through a normal colonic mucosal gland. Staining is much stronger in the surface epithelial cells (solid arrow head) than in 
the crypt epithelial cells (open arrow head). Relationship between amphiregulin and COX-2 expression in human 
colorectal cancer. 6b. Representative paired images of immunocytochemistry for COX-2 (left) and amphiregulin (right) in a 
selection of tumour samples demonstrating a concordance in the localisation of positive staining within individual tumour spec-
imens. Nuclear localisation of amphiregulin expression in colorectal tumour. Figure 6c (Bottom left panel) Focal 
areas of positive amphiregulin staining were observed in the nuclei of tumour cells (representative image with arrow head indi-
cating positive nuclear staining).BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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There are limited data on the relative expression of these
receptors in CRC in humans. A down-regulation of the
EP3 receptor has recently been reported in human color-
ectal tumours [28]. Paradoxically, a study combining
immunocytochemistry and in-situ hybridisation showed
that EP3 and EP4 were the major receptors expressed (in
association with COX-2 induction) in adenomatous pol-
yps in patients with FAP [29]. A further study failed to
demonstrate EP4 receptor or COX-2 mRNA induction in
tumour specimens [30]. However, these observations are
at variance with our findings and those of others [31]. EP4
receptor signalling modulates a tumourigenic phenotype
in cancer cell lines and promotes metastatic potential in-
vivo [31-33]. It has also also been demonstrated as impor-
tant in the pro-neoplastic effects of PGE2 in a range of
other human cancers; notably breast cancer where EP4
has been related to mediation of proliferation, invasion
and metastasis [34,35]. Given its' relative abundance and
functional activity, it seems reasonable to conclude that
EP4 receptor mediates at least some of the important pro-
neoplastic effects of PGE2.
Despite the ability of PGE2 to stimulate cancer cell growth
[16], early data suggested that COX-2 over-expression in
intestinal epithelial cells was associated with a paradoxi-
cal G1 delay [36]. Subsequent data suggest this occurs via
prostaglandin independent mechanisms [37], perhaps
representing an artefact of ectopic COX-2 expression. G0/
G1 cell cycle arrest in cancer cells associated COX-2 inhibi-
tion has also been noted [38] and seems more plausible
given the growth inhibitory effects of NSAIDs. We confirm
the observation of G0/G1 arrest with COX-2 inhibitor
treatment and demonstrate that the effect is PGE2 depend-
ent. We observe that this effect is also produced by the EP4
receptor using a selective receptor antagonist (which
shows similar effects on cellular cAMP concentration).
Our observations are consistent with previous reports of
modulation of cell growth in colon cancer cells through
EP4 and of changes in susceptibility to apoptosis via EP4
receptor activation [16,39,40].
p21WAF1/CIP1 is a cyclin dependent kinase inhibitor which
indirectly regulates pRb phosphorylation and thus the G1
to S phase transition. Induction of p21WAF1/CIP1 expression
has been described in colon cancer cells following treat-
ment with COX-2 selective inhibitors [38,41,42] and
recent observations from other disease models suggest
this is truly a prostanoid dependent event [43]. We dem-
onstrate that selective induction of p21WAF1/CIP1 expres-
sion is associated with EP4 receptor mediated cell cycle
arrest. We also note repression of p21WAF1/CIP1 expression
in colorectal tumours (the majority of which express
COX-2) samples in public expression datasets (Additional
File 1). p21WAF1/CIP1 is one of the few genes which shows
consistent induction in expression in the rectal mucosa of
patients treated with sulindac and deletion of p21WAF1/CIP1
in a mouse model abolished the ability of sulindac to
inhibit Apc-initiated tumourigenesis [44], observations
which reinforce the hypothesis that p21WAF1/CIP1 acts as a
possible downstream effector of COX-2/PGE2/EP4 activ-
ity in CRC.
The EP4 receptor generates intracellular cyclic AMP
(cAMP) via coupling to Gs proteins leading to activation
of protein kinase A (PKA), phosphorylation of cAMP-
response element binding protein (CREB) and PKA-
dependent activation of extracellular signal-related kinase
(ERK)[32]. However, in contrast to EP2 receptors (which
also increase cAMP), EP4 receptors also activate phos-
phatidylinositol 3-kinase (PI3K) dependent signalling
[45]. We did not observe p21WAF1/CIP1 induction in HT-29
cells treated with the PI3K inhibitor wortmanin, however,
p21WAF1/CIP1induction was seen with an EGFR tyrosine
kinase inhibitor. PGE2  transactivates the epidermal
growth factor receptor (EGFR) in HT-29 cells through c-
Src-mediated release of the EGFR ligands [46]. This there-
fore seems the likely mechanism for PGE2/EP4 mediated
changes in p21WAF1/CIP1 expression.
To further clarify the role of EGFR transactivation, we
focussed on the EGFR ligand amphiregulin (AR). AR
expression in colon cancer cells (in culture) is increased by
PGE2 via a cAMP/PKA dependent pathway [47], an effect
therefore mediated through via EP2 or EP4 receptors. AR
is the major EGFR ligand produced by HCA7 cells, where
it acts as an autocrine growth factor [21]. L-161984
(EP4A) has also recently been shown to inhibit HCA7
proliferation [48]. We demonstrate the ability of COX-2
inhibition and AR neutralisation to inhibit HCA7 cell pro-
liferation with an additive effect seen with a combination
of both. This supports observations of the ability of PGE2
to synergistically enhance EGFR receptor tyrosine kinase
signalling [49] and suggests a novel therapeutic approach.
It has been recognised that EGF signalling may be impor-
tant in sustaining elevated COX-2 expression[50], suggest-
ing a positive feedback loop re-inforcing the increased
activity of both pathways. Combined inhibition of COX-
2 and EGFR may be a rational means to attempt to break
this cycle and has shown promise in animal models
[51,52]. Specific targeting of human EGFR with the mon-
oclonal antibody cetuximab is already showing promise
in trials in patients with metastatic CRC [53].
We also studied AR expression in human CRC and
explored its relationship with COX-2 expression. In con-
trast to COX-2, AR showed significant expression in nor-
mal colonic mucosa. Interestingly, a pattern of differential
expression along the colonic crypt is noted, similar to that
previously described for the EP4 receptor [54]. Prior stud-
ies have shown increased AR expression in 50–70% of pri-BMC Cancer 2009, 9:207 http://www.biomedcentral.com/1471-2407/9/207
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mary or metastatic colorectal tumours [55,56]. We
observed a similar trend with 70% of our samples show-
ing significant expression of both COX-2 and AR and con-
cordance observed in the localisation of positive
immunostaining within tumours. Interestingly, AR locali-
sation was not confined to the cytoplasm of tumour epi-
thelium as might be expected of a secreted glycoprotein
(which acts as a ligand for EGFR). The significance of a
nuclear localisation for AR has not been addressed
although the presence of a nuclear localisation sequence
in the AR protein has been noted and AR shows the ability
to interact with nuclear proteins [57]. This raises the fasci-
nating possibility that AR may act as a nuclear effector for
PGE2 in cancer cells, a hypothesis which merits further
evaluation.
Conclusion
In conclusion, while selective COX-2 inhibition for
chemo-prevention of CRC no longer appears a safe thera-
peutic option for the average risk patient due to the risk of
vascular events [9,11], this strategy has shown clinical
effectiveness in reducing incidence of colorectal neoplasia
[8-10]. COX-2 remains an important target for CRC
chemo-prevention, but future strategies must seek to tar-
get the activity of PGE2 in the colonic epithelium, while
minimising effects elsewhere in the body[18]. Targeting of
EP receptors, such as EP4 shows promise [58]. Other effec-
tors such as amphiregulin and p21WAF1/CIP1 also merit
consideration to be targeted alone or in combination with
other downstream molecules.
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